Teva Pharmaceutical Industries Limited (TEVA) |
|
8.44 -0.09 (-1.06%)
|
03-24 16:00 |
|
Open: |
8.42 |
Pre. Close: |
8.53 |
|
High:
|
8.535 |
Low:
|
8.28 |
|
Volume:
|
7,776,217 |
Market Cap:
|
9,375(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:30:27 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 11 One year: 11.84 |
| Support: |
Support1: 8.27 Support2: 6.88 |
| Resistance: |
Resistance1: 9.42 Resistance2: 10.14 |
| Pivot: |
8.92 |
| Moving Average: |
MA(5): 8.6  MA(20): 9.18
MA(100): 9.51 MA(250): 9.03 |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 15.8 %D(3): 20.1 |
| RSI: |
RSI(14): 31.2 |
| 52-week: |
High: 11.44 Low: 6.78 |
| Average Vol(K): |
3-Month: 9,094 (K) 10-Days: 11,021 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TEVA ] has closed above bottom band by 23.5%. Bollinger Bands are 29.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.55 - 8.6 |
8.6 - 8.64 |
|
Low:
|
8.16 - 8.23 |
8.23 - 8.28 |
|
Close:
|
8.35 - 8.45 |
8.45 - 8.53 |
|
Company Description |
|
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel. |
Headline News |
Sat, 25 Mar 2023
Teva Pharmaceutical Industries Limited is acquired by Assenagon ... - Best Stocks
Sat, 25 Mar 2023
DNB Asset Management AS Sells 8900 Shares of Teva ... - Defense World
Fri, 24 Mar 2023
Teva Pharmaceutical Industries Limited (TEVA) Stock Sees a-2.29 ... - The News Heater
Thu, 23 Mar 2023
Teva Pharmaceutical Industries Enters Oversold Territory (TEVA) - Nasdaq
Tue, 21 Mar 2023
Where Does Wall Street Think Teva Pharmaceutical Industries Ltd (TEVA) Stock Will Go? - InvestorsObserver
Mon, 20 Mar 2023
Baker McKenzie advises on USD 2.5 billion (equivalent ... - Baker McKenzie
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
1,110 (M) |
| Shares Float |
1,100 (M) |
|
% Held by Insiders
|
2 (%) |
|
% Held by Institutions
|
49.6 (%) |
|
Shares Short
|
25,570 (K) |
|
Shares Short P.Month
|
28,350 (K) |
Stock Financials |
|
EPS
|
-2 |
|
EPS Est Next Qtl
|
1.09 |
|
EPS Est This Year
|
4.23 |
|
EPS Est Next Year
|
3.69 |
|
Book Value (p.s.)
|
7.11 |
|
Profit Margin (%)
|
-15.8 |
|
Operating Margin (%)
|
17.8 |
|
Return on Assets (ttm)
|
3.6 |
|
Return on Equity (ttm)
|
-24.2 |
|
Qtrly Rev. Growth
|
-5.4 |
|
Gross Profit (p.s.)
|
6.27 |
|
Sales Per Share
|
13.44 |
|
EBITDA (p.s.)
|
3.57 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
1,590 (M) |
|
Levered Free Cash Flow
|
2,900 (M) |
Stock Valuations |
|
PE Ratio
|
-4.25 |
|
PEG Ratio
|
0.9 |
|
Price to Book value
|
1.18 |
|
Price to Sales
|
0.62 |
|
Price to Cash Flow
|
5.89 |
Stock Dividends |
|
Dividend
|
0.09 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
1% |
|
Dividend Pay Date
|
2017-12-11 |
|
Ex-Dividend Date
|
2017-11-26 |
|
Your Ad Here
|
|
